institutional registries demonstrated the feasibility of carotid artery stenting (CAS) as a possible alternative to CEA. Its popularity is due, at least in part, to the perceived advantages of a less invasive treatment for extracranial carotid occlusive disease. Two randomized trials have now compared CAS and CEA. The SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) investigators randomized 334 high-risk patients to CAS or CEA (Yadav et al. 2004 ) and reported no difference in the composite stroke, death and myocardial infarction rate. The European CAVATAS (Carotid and Vertebral Artery Transluminal Angioplasty Study) investigators reported similar results (CAVA-TAS 2001) . Both studies concluded that CAS was not inferior to CEA. These trials were not powered to identify superiority between CAS and CEA. The NIHsupported CREST (Carotid Revascularization Endarterectomy versus Stent Trial) is currently underway to make that determination but the lead-in phase of the trial has yielded low complication rates with CAS (combined stroke and death: 5.6% for symptomatic, 2.4% for asymptomatic patients) (Hobson et al. 2004 ). These results have encouraged the Food and Drug Administration in the United States to approve the use of CAS in selected high-risk individuals. In addition, the NIH has expanded CREST to investigate asymptomatic patients in addition to the symptomatic patients already being recruited.
On the basis of the recommendations of a multidisciplinary panel (Veith et al. 2001 ) specific subgroups of patients (high-risk patients with significant medical co-morbidities and patients with carotid restenosis after previous CEA, anatomically inaccessible lesions above C2, and radiation-induced stenoses) are generally considered candidates for CAS. Furthermore, the FDA has permitted the use of CAS in patients with neurological symptoms (stroke, TIA, AF) in association with severe medical co-morbidities. Meanwhile, the NIH-sponsored CREST is currently underway to obtain level 1 data on the efficacy and risks of CAS compared to CEA.
The procedure requires advanced catheterguidewire skills that have recently been outlined in a consensus document published by the Society for Vascular Surgery (Rosenfield 2005) . While a fixed imaging unit with a large image intensifier may be ideal, the procedure has been safely performed in the operating room with a mobile table and portable Carm. Patients are placed on aspirin 325 mg QD and clopidogrel 75 mg BID at least 2 days prior to the procedure (failing which, a loading dose of 300 mg is given on the day of the procedure). The procedure is performed with the patient supine on the table. The head is placed on a ring, cradle or similar stabilizing support. Care is taken to traverse all EKG wires away from the chest, neck and head to avoid interference with aortic arch, cervical and intracranial angiography. The preferred site for vascular access is the femoral artery. The groin is prepped and draped with four sterile towels to delineate a square area encompassing the palpable femoral pulse. A large drape is then placed over the entire body leaving the face uncovered. Access into the femoral artery is usually gained with a single wall puncture needle and a 0.035-inch guidewire under fluoroscopic guidance. A 5F short sheath is then positioned into the artery. If the femoral arteries are occluded, brachial access The procedure is performed under local infiltration anesthesia with the patient awake. Generally, the patients are not sedated. There must be constant contact with the patient and the patient is usually asked to squeeze an audible device with the contralateral arm to assess gross neurological function during all maneuvers involving instrumentation of the carotid artery. Continuous EKG, oxygen saturation and invasive blood pressure monitoring are mandatory since bradycardia and hypotension may occur during instrumentation of the carotid bulb. Atropine, dopamine, nitroglycerin, oxygen and IV fluids must be readily available in the room. In vivo studies using transcranial Doppler and ex vivo models have demonstrated that carotid stenting releases atheroembolic particles. To reduce the incidence of embolization and possible neurological complications, one of several antiembolic protection devices is recommended. They fall under three major categories: distal filters, distal occlusive balloons, or proximal occlusion and flow reversal systems. Of these, the former two have been most commonly used. Postprocedure, the patients are placed on aspirin 325 mg and clopidogrel 75 mg once daily for at least 4 weeks; aspirin is then continued indefinitely. A baseline duplex ultrasound (DU) examination is performed prior to discharge home. Patients are currently being followed clinically and with a DU at 3, 6, and 12 months, and annually thereafter (Lal et al. 2003) .
Figure 1: Assessment of Arch Anatomy
A 5F diagnostic catheter (pigtail) is advanced over the 0.035-inch guidewire and the tip positioned in the ascending aorta. A power injector set at 900 psi and the image intensifier rotated to a left anterior oblique view allows an appropriate view of the aortic arch branches. A flush arch aortogram is extremely useful in identifying arch anatomic variations, which determines the type of catheter to be used for common carotid cannulation. In most circumstances, this will also allow determination of the extent of carotid stenosis. Once a decision to proceed has been made, the patient is loaded with 100 units/kg of heparin. This is supplemented through the duration of the procedure to maintain an ACT of 250-300 s. Figure 1 is an example of an arch angiogram demonstrating the origins of arch branches as well as a high-grade left internal carotid artery stenosis
